BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Obesity clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for obesity: 500 (179 sponsors; 195 newly posted in the last 180 days, 11 stopped in the last 180 days; 48 new-entrant sponsors). Momentum score 38.5, rank 1 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 3, Phase 1 158, Phase 2 91, Phase 3 155, Phase 4 8, N/A 85.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Eli Lilly and Company LLY59P3 35, P1 13, P2 7, P4 4178
Novo Nordisk A/S NVO70P3 26, P1 27, NA 11, P2 5, P4 12514
Pfizer PFE20P3 13, P1 6, P2 1155
Amgen AMGN18P3 12, P1 4, P2 275
Hoffmann-La Roche12P3 7, P1 3, P2 252
AstraZeneca AZN13P1 5, P3 6, P2 285
Fujian Shengdi Pharmaceutical Co., Ltd.12P1 5, P2 2, P3 558
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.11P1 4, P3 5, P2 232
Innovent Biologics (Suzhou) Co. Ltd.9P3 4, P2 2, P1 332
Hangzhou Sciwind Biosciences Co., Ltd.8P2 3, P1 1, P3 443
Viking Therapeutics, Inc. VKTX6P3 4, P1 241
Boehringer Ingelheim11P1 7, P2 1, P3 384
Regeneron Pharmaceuticals REGN9P3 3, P2 5, P1 142
Kailera KLRA7P2 2, P1 2, P3 322
The United Bio-Technology (Hengqin) Co., Ltd.7P1 3, P3 3, P2 162
Gan & Lee Pharmaceuticals.4P1 1, P3 310
Ascletis Pharma (China) Co., Limited new entrant5P1 3, P3 251
Rhythm Pharmaceuticals, Inc. RYTM5P2 3, P3 202
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics new entrant2P3 220
Harmony Biosciences Management, Inc. HRMY2P3 201
Beijing QL Biopharmaceutical Co.,Ltd8P1 5, P2 2, P3 135
Shanghai Minwei Biotechnology Co., Ltd8P1 5, P3 1, P2 260
BrightGene Bio-Medical Technology Co., Ltd. new entrant3P2 2, P3 131
Chendu DIAO Pharmaceutical Group CO., LTD. new entrant3P1 2, P3 132
Guangdong Raynovent Biotech Co., Ltd3P2 1, P1 1, P3 100

New-entrant sponsors: Ascletis Pharma (China) Co., Limited, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, BrightGene Bio-Medical Technology Co., Ltd., Chendu DIAO Pharmaceutical Group CO., LTD..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P2Skye Bioscience, Inc. SKYENCT06577090 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboObesityactive not recruiting136
2026-11-30 est.P2BioAge Labs, Inc. BIOANCT07656727 A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsObesity and Cardiovascular Riskactive not recruiting160
2026-12 est.P2Shandong Suncadia Medicine Co., Ltd.NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and ObesityAdults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesirecruiting225
2026-12 est.P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06974851 A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and ObesityBstructive Sleep Apnea (OSA) and Obesityrecruiting140
2026-12 est.P3Fujian Shengdi Pharmaceutical Co., Ltd.NCT06994650 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With OSubjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapyactive not recruiting144
2026-12-01 est.P3Vanda Pharmaceuticals VNDANCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseNausea and Vomiting; Obesityrecruiting280
2026-12-12 est.P2Beijing QL Biopharmaceutical Co.,LtdNCT07230132 Efficacy and Safety of ZT006 in Overweight and Obese ParticipantsOverweight , Obesityactive not recruiting184
2026-12-14 est.P2Novo Nordisk A/S NVONCT07184632 A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or ObesityOverweight; Obesityactive not recruiting224
2026-12-31 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)active not recruiting479
2026-12-31 est.P3HK inno.N CorporationNCT07192263 Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes MellitusObesity &Amp; Overweightnot yet recruiting300
2027-01 est.P2Hanmi Pharmaceutical Company Limited HAFCNCT07205900 Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes MellitusObese; Obesityactive not recruiting267
2027-01-05 est.P1/P2Hangzhou Sciwind Biosciences Co., Ltd.NCT07243171 A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With OverweOverweight and/or Obesity; Weight Managementrecruiting126
2027-01-14 est.P2Novo Nordisk A/S NVONCT07395687 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or ObesityOverweight; Obesityrecruiting333
2027-01-21 est.P3Amgen AMGNNCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightObesityactive not recruiting3853
2027-01-21 est.P3Amgen AMGNNCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightType 2 Diabetes Mellitus (T2DM), Obesity, Overweightactive not recruiting1105
2027-01-29 est.P1/P2AstraZeneca AZNNCT06151964 A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightOverweight and Obesityactive not recruiting166
2027-01-31 est.P2NeuroBiogen Co., LtdNCT07009171 Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese PatientsOverweight; Obesity; Obese Patientsrecruiting75
2027-02 est.P3Eli Lilly and Company LLYNCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)Obesity; Overweightrecruiting125
2027-02 est.P1/P2Arrowhead Pharmaceuticals ARWRNCT06937203 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes MellitusObesity; Diabetes Mellitus, Type 2recruiting150
2027-02 est.P2Antag TherapeuticsNCT07724340 A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and OverweighAdults With Overweight/Obesity and Type 2 Diabetesactive not recruiting150
2027-02-01 est.P2AB Biotics, SANCT07193927 Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic TrialMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Fatty Liver Disease, Nonalcoholic;recruiting60
2027-02-04 est.P2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07521631 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesObesityrecruiting372
2027-02-05 est.P2EktaHNCT07882654 A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.Obesity / Overweight; Obesity (BMI Equal to or >30)not yet recruiting31
2027-02-14 est.P3Hudson BiotechNCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbiditiesrecruiting2539
2027-02-14 est.P2Hudson BiotechNCT07505745 MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/ObesityPrediabetes; Insulin Resistance; Overweight/Obesityrecruiting120
2027-02-15 est.P1/P2Ikaria Bioscience Pty LtdNCT07245771 Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination Obesity &Amp; Overweightrecruiting104

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P2Regeneron Pharmaceuticals REGNNCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USOverweight or Obesityactive not recruiting120
2026-11-03P2Rhythm Pharmaceuticals, Inc. RYTMNCT06772597 A Study of Setmelanotide in Patients With Prader-Willi SyndromePrader-Willi Syndrome; Obesity; Hyperphagiaactive not recruiting18
2026-11 est.P3Eli Lilly and Company LLYNCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting465
2026-11 est.P3Eli Lilly and Company LLYNCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or OverweightType 1 Diabetes; Obesity; Overweightactive not recruiting905
2026-11 est.P2KeyBioscience AGNCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with OsteoarthritisOsteoarthritis in the Knee; Obesityrecruiting600
2026-11 est.P3Eli Lilly and Company LLYNCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityObesityactive not recruiting800
2026-10-23 est.P2AstraZeneca AZNNCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / OverweightObesity/Overweightactive not recruiting16
2026-10-15 est.P2EccogeneNCT07505303 MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialAdult Obesity; Weight Managementactive not recruiting151
2026-10 est.P2Shanghai Minwei Biotechnology Co., LtdNCT07791537 Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With OverweightOverweight , Obesityactive not recruiting125
2026-09-30 est.P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe ObesityObesityactive not recruiting98
2026-09-29P1/P2Pfizer PFENCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without DiabetesObesity and Obesity-related Medical Conditionscompleted201
2026-09-24 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityObesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Eactive not recruiting141
2026-09-22P3Gan & Lee Pharmaceuticals.NCT07292441 Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossOverweight or Obesitycompleted224
2026-09-20 est.P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07279194 Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesObesity & Overweightrecruiting825
2026-09-18P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes MellitusObese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Losscompleted58
2026-09-11P2Verdiva Bio Dev LimitedNCT07553299 A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweight; Weight Maintenanceterminated8
2026-09-09P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07169942 Aleniglipron Phase 2 Body Composition StudyObesity, Overweight, or Chronic Weight Managementcompleted71
2026-09-03P2Hoffmann-La RocheNCT06965413 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants WObesity; Overweight; Overweight With One Weight Related Comorbidityactive not recruiting285
2026-09 est.P2Shanghai Minwei Biotechnology Co., LtdNCT07804797 Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or ObesityOverweight , Obesityactive not recruiting71
2026-09 est.P2Biohaven Therapeutics Ltd. BHVNNCT07281495 Taldefgrobep Alfa in Adults With Overweight and ObesityObesity; Overweightactive not recruiting150
2026-08-21P2NodThera Ltd. (a Rezera company)NCT07220629 Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)Obesitycompleted82
2026-08-13P2Zealand Pharma ZEAL.CONCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)Overweight; Type 2 Diabetes; Obesitycompleted221
2026-08-01 est.P3Innovent Biologics (Suzhou) Co. Ltd.NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityOverweight; Obesity; Hypertensiverecruiting336
2026-07-23P2Verdiva Bio Dev LimitedNCT07281937 A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweightcompleted206
2026-07-21P3Eli Lilly and Company LLYNCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightOSA; Overweight or Obesitycompleted712
2026-07-15 est.P2Immunis, Inc.NCT06600581 Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessMuscle Performance; Sarcopenic Obesityactive not recruiting55
2026-07-09P2Shanghai Minwei Biotechnology Co., LtdNCT07791524 Phase 2 Study of MWN109 Tablet in Participants With Overweight or ObesityOverweight , Obesitycompleted255
2026-07-06P2Eli Lilly and Company LLYNCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesOverweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2Dcompleted134
2026-07-01P2Eli Lilly and Company LLYNCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight WObesity; Overweightcompleted367
2026-07 est.P2Aphaia Pharma US LLCNCT07008456 A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel CompObese With Comorbidities; Obese Patients (BMI ≥ 30 kg/m²)recruiting102
2026-06-24P3Rhythm Pharmaceuticals, Inc. RYTMNCT06596135 Open-Label Extension Study of SetmelanotideObesity Associated With Defects in Leptin-melanocortin Pathwaycompleted28
2026-06-16P2Regeneron Pharmaceuticals REGNNCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for WeigObesitycompleted1005
2026-06-16P3Eli Lilly and Company LLYNCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightType 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apneacompleted1152
2026-06-15 est.P3Guangdong Raynovent Biotech Co., LtdNCT06893016 Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are OverweightObesityrecruiting640
2026-06-02P3Eli Lilly and Company LLYNCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesObesity; Overweightactive not recruiting160
2026-06-01P3Boehringer IngelheimNCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)Obesitycompleted5530
2026-05-30 est.P3Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT06885021 Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese AdultsOverweight and Obesitynot yet recruiting780
2026-05-30 est.P3Hangzhou Jiuyuan Gene Engineering Co. Ltd.,NCT06633783 A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®Obesityunknown370
2026-05-29P2Carmot Therapeutics, Inc.NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusOverweight or Obese; Type 2 Diabetes Mellitus (T2DM)completed447
2026-05-27P2NodThera Ltd. (a Rezera company)NCT07055516 Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes MellitusObesity and Type 2 Diabetescompleted176
2026-05-26P2AstraZeneca AZNNCT06851858 Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor AEndocrinology; Diabetes, Type II; Obesitycompleted69

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "obesity"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.